Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin ® ) in patients with HER2-positive metastatic breast cancer
ConclusionsPF-05280014 and trastuzumab-EU had similar PK parameters and influential PK covariates in patients with HER2-positive mBC. These results provided further evidence in patients for PK similarity between PF-05280014 and trastuzumab-EU.Clinical trial registrationClinicalTrials.gov, NCT01989676.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Drugs & Pharmacology | HER2 | Herceptin | Japan Health | Study